Sanofi has revealed that it has agreed a deal with SK Chemicals, a South Korean vaccine manufacturer, to license its cell culture technology in a $155 million deal.
The deal sees SK Chemicals receive $15 million up-front and a further $20 million once the technology has been transferred – the rest of $120 million is locked into milestone payments; there are also royalties tied to net sales of any product arising from the partnership.
